The management of myasthenia.
D000328:Adult; D000549:Ambenonium Chloride / Q000627:therapeutic use; D002283:Carcinoma, Bronchogenic / Q000150:complications; D004809:Ephedrine / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006980:Hyperthyroidism / Q000150:complications; D008175:Lung Neoplasms / Q000150:complications; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000150:complications; D009157:Myasthenia Gravis / Q000150:complications / Q000175:diagnosis / Q000209:etiology / Q000276:immunology / Q000601:surgery*; D009220:Myositis / Q000150:complications; D009388:Neostigmine / Q000627:therapeutic use; D009801:Oculomotor Muscles; D010830:Physostigmine / Q000627:therapeutic use; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D013934:Thymectomy; D013945:Thymoma / Q000150:complications; D013953:Thymus Neoplasms / Q000150:complications
D009388:Neostigmine; D000549:Ambenonium Chloride; D010830:Physostigmine; D004809:Ephedrine; D011729:Pyridostigmine Bromide